A randomised, double-blinded clinical study of LC for systemic lupus erythematosus patients
Not Applicable
Completed
- Conditions
- Systemic lupus erythematosus (SLE)Musculoskeletal Diseases
- Registration Number
- ISRCTN81818883
- Lead Sponsor
- Department of Health (Taiwan) - Executive Yuan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
1. Patients fulfill the revised American College of Rheumatology (ACR) criteria for systemic lupus erythematosus (SLE)
2. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score more than or equal to 2 and less than or equal to 36
3. Daily dose of prednisolone less than or equal to 0.6 mg/kg
4. Age more than or equal to 7 years old and body weight more than or equal to 40 kg, either sex
Exclusion Criteria
1. Alcoholism
2. Diabetes mellitus
3. Life-threatening disease
4. Pregnant or nursing women
5. Creatinine clearance less than or equal to 25 cc/min
6. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) more than or equal to 2 x normal limit
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method